GX1 Stock Overview
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Marker Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.68 |
| 52 Week High | US$5.30 |
| 52 Week Low | US$2.12 |
| Beta | 1.49 |
| 11 Month Change | -24.72% |
| 3 Month Change | -14.10% |
| 1 Year Change | n/a |
| 33 Year Change | -74.95% |
| 5 Year Change | -90.16% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| GX1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.6% | -0.7% | -0.02% |
| 1Y | n/a | -17.2% | 8.2% |
Return vs Industry: Insufficient data to determine how GX1 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how GX1 performed against the German Market.
Price Volatility
| GX1 volatility | |
|---|---|
| GX1 Average Weekly Movement | 16.9% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: GX1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: GX1's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 8 | Juan Vera | markertherapeutics.com |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer.
Marker Therapeutics, Inc. Fundamentals Summary
| GX1 fundamental statistics | |
|---|---|
| Market cap | €26.56m |
| Earnings (TTM) | -€9.25m |
| Revenue (TTM) | €5.18m |
5.1x
P/S Ratio-2.9x
P/E RatioIs GX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GX1 income statement (TTM) | |
|---|---|
| Revenue | US$5.40m |
| Cost of Revenue | US$2.62m |
| Gross Profit | US$2.78m |
| Other Expenses | US$12.41m |
| Earnings | -US$9.63m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 51.49% |
| Net Profit Margin | -178.54% |
| Debt/Equity Ratio | 0% |
How did GX1 perform over the long term?
See historical performance and comparison